The FDA is planning a resumption of inspections of pharmaceutical manufacturing

American regulators are working on a phased plan for the resumption of inspections of pharmaceutical factories, which was suspended due to the spread of coronavirus infection. The work is conducted jointly with the Centers for control and prevention (CDC), told the FDA.

In March, the FDA announced the suspension of inspection of manufacturing sites due to contamination risk employees COVID-19. The regulator said that the risk to inspectors are higher than for consumers in case of supply to the market drugs of poor quality. Instead of the usual inspections for quality control of drugs was carried out product testing at the border, and in case of revealing the poor quality of imported drugs was prohibited.

While continuing pandemic, U.S. regulators will continue to use alternative methods of quality control, inspections will not be performed until they are needed in the field of health.

However, together with CDC experts, the FDA started working on a plan for the resumption of control measures. For starters will be determined “when and where” in the future to begin inspections to ensure the safety of the inspectors.

Leave a Reply

Your email address will not be published. Required fields are marked *


For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]